Working… Menu

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03277482
Recruitment Status : Recruiting
First Posted : September 11, 2017
Last Update Posted : August 31, 2021
Information provided by (Responsible Party):
Martin King, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : January 2022